Direct targeted therapy for MLL-fusion-driven high-risk acute leukaemias. (2022)
Attributed to:
Establishing the mechanism for RUVBL2 essentiality in acute myeloid leukaemia
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1002/ctm2.933
PubMed Identifier: 35730653
Publication URI: http://europepmc.org/abstract/MED/35730653
Type: Journal Article/Review
Volume: 12
Parent Publication: Clinical and translational medicine
Issue: 6
ISSN: 2001-1326